Ars Pharmaceuticals, Inc. (SPRY)
NASDAQ:SPRY
SPRY Stock Chart & Stats
$8.30
-$0.02(-0.18%)
At close: 4:00 PM EST
$8.30
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$6.66 - $18.90
Previous CloseN/A
Volume456.05K
Average Volume (3M)1.46M
Market Cap
$799.34M
Enterprise Value$854.99M
Total Cash (Recent Filing)$244.99M
Total Debt (Recent Filing)$96.96M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
May 19, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding99,297,310
10 Day Avg. Volume1,389,890
30 Day Avg. Volume1,460,486
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)10.05
Price to Sales (P/S)13.63
P/FCF Ratio-6.71
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue10.14
Enterprise Value/Gross Profit13.39
Enterprise Value/Ebitda-4.99
Forecast
1Y Price Target
$27.50Price Target Upside231.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.47
Revenue Forecast (FY)$160.28M
Bulls Say, Bears Say
Bulls Say
Competitive DynamicsA competitor received an FDA complete response letter over administration and labeling issues, which could delay that rival’s market entry and reduce near-term competitive pressure.
Labeling And UsabilityFDA label updates removed prior age restrictions and allowed practical administration changes such as sniffing and post-thaw use, increasing real-world usability and expanding the eligible pediatric and adult patient population.
Salesforce Expansion And MarketingExpansion of the salesforce funded by reallocating existing resources, together with direct-to-consumer campaigns and an integrated virtual prescribing program, is positioned to raise prescriber engagement and broaden patient awareness.
Bears Say
Demand Volatility And Execution RisksCompany-reported headwinds limited the ability to fully capture seasonal demand peaks, highlighting sensitivity to timing and execution that could affect short-term sales momentum.
Insurance Formulary AccessNarrow insurance coverage and the need for formulary wins remain major barriers to broader adoption, making payer agreements critical for scaling use.
Medicaid Coverage GapsLimited adoption of the product across state Medicaid programs could constrain access expansion and slow overall prescription growth.
ARS Pharmaceuticals News
SPRY FAQ
What was Ars Pharmaceuticals, Inc.’s price range in the past 12 months?
Ars Pharmaceuticals, Inc. lowest stock price was $6.66 and its highest was $18.90 in the past 12 months.
What is Ars Pharmaceuticals, Inc.’s market cap?
Ars Pharmaceuticals, Inc.’s market cap is $799.34M.
When is Ars Pharmaceuticals, Inc.’s upcoming earnings report date?
Ars Pharmaceuticals, Inc.’s upcoming earnings report date is May 19, 2026 which is in 37 days.
How were Ars Pharmaceuticals, Inc.’s earnings last quarter?
Ars Pharmaceuticals, Inc. released its earnings results on Mar 09, 2026. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.02.
Is Ars Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Ars Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Ars Pharmaceuticals, Inc. pay dividends?
Ars Pharmaceuticals, Inc. does not currently pay dividends.
What is Ars Pharmaceuticals, Inc.’s EPS estimate?
Ars Pharmaceuticals, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Ars Pharmaceuticals, Inc. have?
Ars Pharmaceuticals, Inc. has 99,297,310 shares outstanding.
What happened to Ars Pharmaceuticals, Inc.’s price movement after its last earnings report?
Ars Pharmaceuticals, Inc. reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went down -0.11%.
Which hedge fund is a major shareholder of Ars Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.50 (231.33% Upside)
$27.50 (231.33% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 47.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.19%
12-Months-Change
Fundamentals
Return on Equity
-100.29%
Trailing 12-Months
Asset Growth
-6.69%
Trailing 12-Months
Company Description
Ars Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
SPRY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed solid early commercial traction and meaningful operational progress: first full-year net product revenue of $72.2M, strong aided awareness gains (20% to 60%), >22,500 prescribers with 50% repeat writers, a $245M cash runway, and encouraging real-world effectiveness data (~90% single-dose success). However, growth is constrained by structural market dynamics (refill dominance, e-prescribing, prior authorization), a high gross-to-net impact (~low- to mid-50% range), and substantial SG&A spending ($230.1M) relative to current product revenue. Management outlined concrete mitigation actions—salesforce expansion funded via reallocation, continued DTC/digital conversion (getneffy.com ~10% of scripts), and ongoing payer negotiations—that suggest a pathway to steadier growth and eventual refill-driven renewals in late 2026–2027. Overall, positives around adoption, awareness, cash sufficiency, and product performance slightly outweigh the near-term commercialization and margin headwinds.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$27.50
▲(231.33% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---